Search Results
Your search for ,ARE matches 21421 pages
Showing 3351 - 3400Effect of Baseline Immunosuppression on COVID-19 Severity and Risk of Cytokine Storm in Patients Receiving Immunotherapy for Cancer
In a registry-based retrospective cohort study reported in JAMA Oncology, Ziad Bakouny, MD, and colleagues in the COVID-19 and Cancer Consortium (CCC19 registry) found that patients receiving cancer immunotherapy who had baseline immunosuppression, but not those without baseline immunosuppression,...
Cost-Effectiveness of Polatuzumab Vedotin-piiq Plus R-CHP and CAR T-Cell Therapy vs Standard of Care in DLBCL
In a study reported in the Journal of Clinical Oncology, Vijenthira et al found that front-line polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), second-line chimeric antigen receptor (CAR) T-cell therapy, or the combination would not be likely to be...
Study Examines Potential Factors Leading to Recurrence of Cancers Caused by BRCA Mutations
Researchers have discovered the factors that may make breast and ovarian cancers associated with BRCA1 and BRCA2 gene mutations more likely to recur, according to new findings published by Shah et al in Nature Communications. These mutations are known to strongly predispose women to breast and...
CAR T-Cell Therapy Outcomes Similar Across Different Socioeconomic Levels Among Patients With Pediatric ALL
Although socioeconomic status often influences survival outcomes, pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who were living in poverty and were treated with CAR T-cell therapy achieved similar overall survival and were equally likely to achieve a complete...
Presence of Small Subclonal Populations of High-Risk Genetic Events at Diagnosis in Multiple Myeloma
In a study reported in the Journal of Clinical Oncology, Lannes et al found that single-cell genomics could identify the presence of high-risk copy number abnormalities (CNAs) in small subclonal populations at diagnosis of multiple myeloma in many patients. The investigators stated, “Multiple...
Evaluation of Plasmid DNA Vaccine Encoding HER2 Intracellular Domain in Patients With Advanced HER2-Positive Breast Cancer
In a single-institution phase I study reported in JAMA Oncology, Disis et al found that a plasmid DNA vaccine encoding the HER2 intracellular domain (ICD) was associated with primarily low-grade toxicity and induced HER2-specific type 1 T-cell responses in patients with advanced HER2-positive...
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation
On June 22, 2022, dabrafenib in combination with trametinib was granted accelerated approval for treatment of adult and pediatric patients (aged 6 and older) with unresectable or metastatic solid tumors with BRAF V600E mutation whose disease progressed following prior treatment and who have no...
Margetuximab-cmkb vs Trastuzumab With Chemotherapy in Previously Treated Advanced HER2-Positive Breast Cancer: Final Overall Survival Analysis of the SOPHIA Trial
As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the final overall survival results of the pivotal phase III SOPHIA trial have shown no significant difference between margetuximab-cmkb plus chemotherapy vs trastuzumab plus chemotherapy in previously...
Cemiplimab-rwlc in Combination With Platinum-Based Chemotherapy in Advanced NSCLC With No EGFR, ALK, or ROS1 Aberrations
On November 8, 2022, cemiplimab-rwlc was approved for use in combination with platinum-based chemotherapy for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1aberrations.1 Supporting Efficacy Data Approval was supported by findings in the...
Moderate Exercise May Help Reduce Inflammation, Increase Survival in Patients With Colorectal Cancer by Improving Gut Microbiota
After examining the impact of exercise on the gut microbiome of patients with cancer and reporting a positive association, researchers discovered that regular physical activity may extend the survival of patients with colorectal cancer, according to a new study published by Himbert et al in the...
Study Shows That Immune Cells May Help Identify Patients With High-Risk Smoldering Myeloma Most Likely to Benefit From Treatment
For many patients who have smoldering myeloma, early treatment can slow or delay the disease’s progression to multiple myeloma, according to a new study published by Sklavenitis-Pistofidis et al in Cancer Cell. Investigators demonstrated that changes in immune system cells may indicate which cases...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, who was not involved in the phase II trial of prophylactic radiation for bone metastases, commented: “I thought this was a very important study. We will need to see the details in the final paper, but this approach could make a meaningfuldifference in the quality of life for...
Randomized Phase II Trial Shows Benefits of Prophylactic Radiation Therapy for Asymptomatic Bone Metastases
The use of prophylactic radiation therapy for patients with metastatic cancer who had asymptomatic, high-risk bone metastases reduced the incidence of skeletal-related events, reduced pain and the number of hospitalizations, and was associated with significantly longer overall survival compared...
Prophylactic Bilateral Mastectomy Among Women With Breast Cancer and Pathogenic Variants in High-Penetrance and Moderate-Penetrance Genes
In a study reported in JAMA Oncology, Reid et al found that undergoing prophylactic bilateral mastectomy was as common in women with breast cancer with pathogenic/likely pathogenic variants in ATM and CHEK2 (moderate-penetrance genes) as in those with variants in BRCA1, BRCA2, or PALB2...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
2022 State of Lung Cancer Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives
The 2022 State of Lung Cancer report by the American Lung Association revealed that only 5.8% of eligible Americans had been screened for lung cancer in 2021, and some states had screening rates as low as 1%. The 5th annual report highlighted how the toll of lung cancer varied by state and examined ...
Used as a Biomarker, MicroRNA May Help Predict Which Patients With Breast Cancer Are More Likely to Have Cancer Recurrence
MicroRNA may be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to a new study published by Davey et al in the Journal of the American College of Surgeons. While long-term outcomes have improved for patients with breast cancer, 20%...
Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
On September 2, 2022, durvalumab was approved for use in combination with gemcitabine/cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind TOPAZ-1 trial (ClinicalTrials.gov...
Talal El Zarif, MD, and Abdul Rafeh Naqash, MD: For Patients Living With HIV and Cancer, New Data on Immune Checkpoint Inhibitors
Talal El Zarif, MD, of Dana-Farber Cancer Institute, and Abdul Rafeh Naqash, MD, of Stephenson Cancer Center at The University of Oklahoma, discuss the results of their cohort study of patients living with HIV and metastatic non–small cell lung cancer, who are often underrepresented in clinical...
Prevalence of Tumor Thrombus at RCC Diagnosis and Risk of Venous Thromboembolism
In a Dutch single-institution retrospective cohort study reported in JACC: CardioOncology, Kaptein et al identified the prevalence of venous tumor thrombus at diagnosis in patients with renal cell carcinoma (RCC) and the associated risk of venous thromboembolism. Study Details The study included...
Fracture Risk Among Older Cancer Survivors
In a study reported in JAMA Oncology, Rees-Punia et al found that the risk of frailty-related bone fractures among older cancer survivors was significantly greater vs that among older adults without a history of cancer. Study Details The longitudinal cohort study used data from 92,431 older adults...
New Research Highlights Disparities in Receipt of Guideline-Concordant Treatment Among Patients With Ovarian Cancer
New research examining whether patients with ovarian cancer were receiving care concordant with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) found clear disparities based on patients’ race, ability to pay, and access to specialists and...
Nationwide Study Finds Higher Rates of Cancer Mortality, Increasing Cases of Early-Onset Colorectal Cancer Among American Indian and Alaska Native Individuals
New findings revealed that overall cancer mortality among American Indian and Alaska Native patients was 18% higher than among White patients despite similar cancer incidence, according to a new study published by Kratzer et al in CA: A Cancer Journal for Clinicians. The findings included the first ...
Researchers Identify Subset of Patients With Stage I Melanoma Who Have Low Risk of Melanoma Mortality
Researchers identified a subset of patients who had early-stage melanoma with almost no melanoma-related deaths, potentially representing cases contributing to overdiagnosis, according to a new study published by Eguchi et al in Cancer. The findings may help clinicians determine which patients have ...
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received...
New Phase I/II Data on the CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma
New data from an ongoing phase II trial evaluating first-line intratumoral administration of sotigalimab, a CD40 agonist antibody, in combination with systemic pembrolizumab, an anti–PD-1 antibody, in metastatic melanoma was presented by Bentebibel et al at the Society for Immunotherapy of Cancer...
Prevalence of Mismatch Repair Deficiency in Rectal Adenocarcinoma in a Prospective Screening Program
As reported in a letter published in The New England Journal of Medicine by Papke et al, data from a prospective biopsy screening program at a large gastrointestinal pathology group indicate that approximately 3% of rectal adenocarcinomas are mismatch repair (MMR)-deficient. Study Background As...
Rare Germline ATM Variants in Chronic Lymphocytic Leukemia
In a single-institution analysis reported in the Journal of Clinical Oncology, Benjamin L. Lampson, MD, and colleagues found a higher prevalence of rare germline ATM variants in chronic lymphocytic leukemia (CLL) vs other lymphoid and myeloid disorders. They also determined that patients with CLL...
First-Line Pembrolizumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC Without EGFR/ALK Alterations
As reported in the Journal of Clinical Oncology by Gilberto de Castro, Jr, MD, PhD, and colleagues, 5-year follow-up of the KEYNOTE-042 trial showed a maintained overall survival benefit with first-line pembrolizumab vs chemotherapy in patients with non–small cell lung cancer (NSCLC) with a PD-L1...
Immune Checkpoint Inhibitors for Patients Living With HIV: Safe and Effective in Metastatic NSCLC
Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented by El Zarif et al at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Abstract 437). Findings from the first matched...
Hormone Therapy May Lower Risk of Immune Checkpoint Inhibitor–Associated Myocarditis in Female Patients
Researchers may have discovered the underlying cause of sex differences in immune checkpoint inhibitor–associated myocarditis after immune checkpoint inhibitor treatment, according to a novel study published by Zhang et al in Science Translational Medicine. Their findings pointed to possible...
CNS-Directed Therapy and Neurocognitive Outcomes in Survivors of Childhood ALL Receiving No Cranial Irradiation
In a single-institution study reported in the Journal of Clinical Oncology, Jacola et al found that survivors of childhood acute lymphoblastic leukemia (ALL) who received central nervous system (CNS)-directed therapy excluding cranial irradiation had poorer outcomes in numerous neurocognitive...
My White Coat Doesn’t Fit
There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main takeaway is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to...
Expert Point of View: Glenn J. Hanna, MD, and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Yuan Yuan, MD, PhD, Joins Cedars-Sinai Cancer Medical Center as Director of Breast Oncology
Cedars-Sinai Cancer Medical Center recently announced the appointment of Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, as Director of Breast Oncology. Finding Cutting-Edge Therapies...
SWOG Names Don S. Dizon, MD, Vice Chair for Diversity, Equity, Inclusion, and Professional Integrity
After nearly a year-long search, the Southwest Oncology Group (SWOG) has announced its new Vice Chair for Diversity, Equity, Inclusion (DEI), and Professional Integrity: Don S. Dizon, MD, who is currently Chair of the organization’s Digital Engagement Committee. Dr. Dizon is Director of the Pelvic...
Phase III FRESCO-2 Trial of Fruquintinib Meets Primary Endpoint in Metastatic Colorectal Cancer
HUTCHMED (China) Limited recently announced that the global phase III FRESCO-2 trial evaluating the investigational use of the anti–vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory...
Expert Point of View: Shom Goel, MBBS, PhD
The invited discussant of the post hoc analysis of TROPiCS-02 was Shom Goel, MBBS, PhD, Laboratory Group Leader at the University of Melbourne and a consultant oncologist at the Peter MacCallum Cancer Centre in Australia. Dr. Goel noted there remains much to learn about the HER2-low subset of...
ASCO Releases Updated Resource-Stratified Guideline for the Secondary Prevention of Cervical Cancer
A new resource-stratified ASCO guideline update provides new evidence-based recommendations for the secondary prevention of cervical cancer in various resource settings.1 In the updated guideline, the screening recommendations cover basic, limited, enhanced, and maximal resource settings. Since...
TROPiCS-02: Efficacy of Sacituzumab Govitecan Within HER2-Negative Subsets of Breast Cancer
In a post hoc analysis of the phase III TROPiCS-02 trial, sacituzumab govitecan-hziy improved efficacy outcomes in HER2-negative immunohistochemistry (IHC) subgroups.1 Results were consistent with those of the intent-to-treat population of hormone receptor–positive/HER2-negative advanced breast...
Study Sheds Light on Need for Optimal Dosing Standards for Patients With Metastatic Cancer
A new study, published recently in JCO Oncology Practice, found that oncologists have different perspectives on how to select starting doses for patients with metastatic cancer.1 The study shared findings from a 2021 international survey of 367 medical oncologists who treat patients with metastatic ...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA
An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...
Expert Point of View: Ignacio Melero, MD, PhD
Ignacio Melero, MD, PhD, Professor of Immunology and Co-Director of the Department of Immunology and Immunotherapy at the Clinica Universidad de Navarra in Spain, was the invited discussant of the M14TIL study. He noted that a 50% relative reduction in the risk of disease progression is impressive...
Prolonging Remission in Anti–PD-1 Refractory Melanoma With Tumor-Infiltrating Lymphocyte Therapy
For the first time in a multicenter randomized trial, T-cell therapy has been shown to improve outcomes in a solid tumor. In the phase III M14TIL trial, first-line or second-line treatment with tumor-infiltrating lymphocytes (TIL) led to a 50% reduction in disease progression or death from advanced ...
UChicago Medicine Names New Associate Director of Cancer Prevention and Population Sciences
Jasmin A. Tiro, PhD, MPH, has joined the University of Chicago Medicine Comprehensive Cancer Center as the new Associate Director of Cancer Prevention and Population Sciences. Dr. Tiro was formerly Professor of Population and Data Sciences at Harold C. Simmons Comprehensive Cancer Center at The...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
Expert Point of View: Anand Devaraj, MD, PhD
Abstract discussant Anand Devaraj, MD, PhD, Professor in Thoracic Radiology at Royal Brompton and Harefield Hospitals, and Professor of Thoracic Radiology at the National Heart and Lung Institute, Imperial College London, highlighted the increased risk of second primary tumors among current...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
